Bedrijfsvoering Gilead Sciences, Inc.

GILD

US3755581036

Farmaceutische producten

Geschatte realtime Cboe BZX Andere beurzen 16:30:40 13-09-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
82,47 ^USD	+0,10%		+5,01%	+2,04%

13:00	Marengo Therapeutics, Inc. Kondigt samenwerking aan voor klinische studies met Gilead Sciences voor de evaluatie van Invikafusp alfa (STAR0602) en Trodelvy in zowel gemetastaseerde TNBC als gemetastaseerde HR+/HER2-borstkanker	CI
12/09	Gilead Sciences zegt dat tweejaarlijkse HIV-behandeling lenacapavir infecties met 96% vermindert	MT

Uitvoerend comité: Gilead Sciences, Inc.

Bedrijfsleider

Beklede functiesVan

Daniel O'Day

59 jaar

Chief Executive Officer

01-03-2019

Sarah Miksinski

General Counsel

Sandra Patterson

57 jaar

Comptroller/Controller/Auditor

01-03-2023

Deborah Telman

59 jaar

General Counsel	01-08-2022
Corporate Secretary	01-08-2022

Flavius Martin

Chief Tech/Sci/R&D Officer

12-04-2021

Jacquie Ross

Investor Relations Contact

01-01-2021

Merdad Parsey

61 jaar

Chief Tech/Sci/R&D Officer

01-11-2019

Jyoti Mehra

48 jaar

Human Resources Officer

01-11-2017

Andrew Dickinson

54 jaar

Director of Finance/CFO

01-11-2019

Samenstelling van de raad van bestuur: Gilead Sciences, Inc.

Directeur

RadenVan

Daniel O'Day

59 jaar

Chairman

01-03-2019

Anthony Welters

69 jaar

Governance Committee
Nominating Committee
Compensation Committee Chair	27-10-2015
Compensation Committee	17-10-2020
HR Committee	17-10-2020
Governance Committee Chair	12-05-2021
Nominating Committee Chair	12-05-2021

Harish M. Manwani

70 jaar

HR Committee	09-05-2018
Governance Committee	12-05-2021
Nominating Committee	12-05-2021
Compensation Committee	09-05-2018

Ted Love

65 jaar

Governance Committee Chair
Nominating Committee Chair
Compensation Committee Chair	03-08-2023
Audit Committee	01-02-2024

Kelly Kramer

56 jaar

Compensation Committee	01-12-2020
HR Committee
Audit Committee Chair	01-12-2020
Audit Committee	01-02-2020

Sandra Horning

75 jaar

Governance Committee	28-01-2020
Nominating Committee	28-01-2020

Jacqueline Barton

71 jaar

Compensation Committee	01-01-2018
HR Committee	01-01-2018

Javier Rodriguez

53 jaar

Audit Committee

15-06-2020

Jeffrey Bluestone

70 jaar

Executive Committee

09-04-2020

Recente benoemingen: Gilead Sciences, Inc.

Cytokinetics, Incorporated kondigt de benoeming aan van Brett Pletcher tot Executive Vice President en Chief Legal Officer	15/08	CI
Fate Therapeutics, Inc. benoemt Neely Mozaffarian tot lid van de Raad van Bestuur	31/07	CI
Gilead Sciences medisch directeur Merdad Parsey vertrekt	17/07	MT
Merdad Parsey verlaat Gilead Sciences, Inc. als Chief Medical Officer, begin 2025	17/07	CI
Sectorupdate: Aandelen gezondheidszorg stijgen dinsdagmiddag	04/06	MT
Gilead Sciences, Inc. kondigt aan dat Kevin E. Lofton zich terugtrekt uit de Raad van Bestuur, met ingang van 8 mei 2024	14/03	CI
AI-Media Technologies benoemt voorzitter; aandelen stijgen 15%	26/02	MT

Meer nieuws

Voormalige zaakvoerders en bestuurders: Gilead Sciences, Inc.

Insider

Beklede functies

VanTot

Kevin Lofton

Director/Board Member	29-07-2009	08-05-2024
Independent Dir/Board Member	29-07-2009	08-05-2024

Brett Pletcher

Compliance Officer	-	01-08-2022
General Counsel	31-03-2011	01-08-2022
Corporate Officer/Principal	01-01-2005	31-03-2011
Corporate Secretary	-	01-08-2022

Tai Yin Yang

Corporate Officer/Principal

01-01-2005

18-07-2022

Amy E. Flood

Public Communications Contact

01-06-2021

William Lee

Chief Tech/Sci/R&D Officer

01-01-1991

12-04-2021

Richard Whitley

Director/Board Member	01-07-2008	01-01-2021
Independent Dir/Board Member	01-07-2008	01-01-2021

Robin Washington

Comptroller/Controller/Auditor	05-05-2008	01-11-2019
Director of Finance/CFO	05-05-2008	01-11-2019

Gregg Alton

Chief Executive Officer	01-01-2019	01-03-2019
Compliance Officer	01-01-1999	-
Public Communications Contact	04-08-2009	09-05-2012
General Counsel	01-01-1999	04-08-2009
Corporate Officer/Principal	01-03-2019	04-10-2019
Corporate Secretary	01-01-1999	-

John McHutchison

Chief Tech/Sci/R&D Officer	01-03-2018	02-08-2019
Corporate Officer/Principal	08-06-2010	01-03-2018

John Martin

Chief Executive Officer	01-01-1996	10-03-2016
Chairman	01-06-2008	01-03-2019

John Milligan

Director/Board Member	28-01-2016	31-12-2018
Chief Executive Officer	10-03-2016	31-12-2018
Chief Operating Officer	01-01-2007	10-03-2016
President	01-01-2008	31-12-2018

Andrew Cheng

Chief Tech/Sci/R&D Officer	-	07-09-2018
Corporate Officer/Principal	01-01-1999	-

Norbert W. Bischofberger

Chief Tech/Sci/R&D Officer	01-01-1995	30-04-2018
Corporate Officer/Principal	01-08-1990	01-01-1995

James Meyers

Corporate Officer/Principal

01-01-1996

22-02-2018

John Madigan

Director/Board Member	01-12-2005	10-05-2017
Independent Dir/Board Member	22-07-2011	10-05-2017

Paul Carter

Corporate Officer/Principal

01-04-2006

01-08-2016

Kevin B. Young

Corporate Officer/Principal	01-09-2004	04-02-2014
Chief Operating Officer	24-05-2016	-

Gordon Earle Moore

Director/Board Member	01-01-1996	31-05-2013
Independent Dir/Board Member	22-07-2011	31-05-2013

James M. Denny

Director/Board Member	01-01-1996	31-05-2013
Independent Dir/Board Member	22-07-2011	31-05-2013

Susan T. Hubbard

Investor Relations Contact

01-09-1989

01-06-2012

Alan Montgomery

Corporate Officer/Principal

01-08-2006

01-05-2011

Anthony D. Caracciolo

Corporate Officer/Principal

01-01-1997

01-10-2010

Per Wold-Olsen

Director/Board Member	28-01-2010	-
Independent Dir/Board Member	28-01-2010	-

Louis Lange

Corporate Officer/Principal

20-04-2009

Seigo Izumo

Corporate Officer/Principal

01-09-2008

Caroline Dorsa

Director of Finance/CFO

05-11-2007

17-01-2008

Howard Rosen

Corporate Officer/Principal

01-01-2004

01-01-2008

Carla A. Hills

Director/Board Member	01-01-2007	-
Independent Dir/Board Member	22-07-2011	-

Kristen M. Metza

Human Resources Officer

01-01-2006

Steven Fife

Comptroller/Controller/Auditor

01-01-2005

01-01-2006

John Francis Cogan

Director/Board Member	01-07-2005	-
Independent Dir/Board Member	01-07-2005	-

Nicholas G. Moore

Director/Board Member	01-03-2004	-
Independent Dir/Board Member	01-03-2004	-

Karl G. Trass

General Counsel

01-01-2003

01-07-2003

James Sapirstein

Sales & Marketing

01-06-2000

01-06-2002

Rebecca Coleman

Director/Board Member

02-01-2000

Michael W. Aguiar

Director of Finance/CFO

01-01-2002

Robert L. Simon

General Counsel

01-07-2000

01-12-2001

Gayle Edlund Wilson

Director/Board Member	01-10-2001	-
Independent Dir/Board Member	01-10-2001	-

Jeff Bird

Corporate Officer/Principal

01-01-2000

Kenneth Cundy

Corporate Officer/Principal

01-01-1992

01-01-2000

Mark D. Matteucci

Corporate Officer/Principal

01-01-1988

01-01-1999

Louis C. Bock

Corporate Officer/Principal

01-09-1989

Robert J. Stagg

Chief Tech/Sci/R&D Officer

01-08-1993

01-12-1996

Bill Harris

Director of Finance/CFO

01-01-1990

01-01-1996

Michael Bigham

Chief Operating Officer	01-01-1988	01-01-1996
Director of Finance/CFO	01-01-1988	01-01-1996

George Pratt Shultz

Director/Board Member

01-01-1996

John Latham

Corporate Officer/Principal

01-01-1989

01-01-1994

Étienne Francois Davignon

Director/Board Member	01-09-1990	-
Independent Dir/Board Member	22-07-2011	-

John J. Toole

Corporate Officer/Principal

01-04-1990

Akram Bouchenaki

Corporate Officer/Principal

Nicholas S. Hellmann

Corporate Officer/Principal

Joseph M. Baini

Corporate Officer/Principal

Wenjin Yang

Corporate Officer/Principal

James V. Desiderio

Corporate Officer/Principal

Jim Ziegler

Sales & Marketing

George Tidmarsh

Corporate Officer/Principal

Erin Edgley

Public Communications Contact

Patrick O'Brien

Investor Relations Contact

Sunil Patel

Corporate Officer/Principal

Dirk B. Mendel

Corporate Officer/Principal

Jeffrey Rudy

Corporate Officer/Principal

Gulshan H. Shaver

Corporate Officer/Principal

Gary C. Visor

Corporate Officer/Principal

Roger G. Mills

Corporate Officer/Principal

Julie Cherrington

Corporate Officer/Principal

Cordell W. Hull

Director/Board Member

David Brogan

Corporate Officer/Principal

Jeffery P. Davis

Corporate Officer/Principal

Mark Italia

General Counsel

Richard J. Gorczynski

Corporate Officer/Principal

Pamela Goss

Corporate Officer/Principal

Adam Tomasi

Corporate Officer/Principal

Robert L. St. Claire

Corporate Officer/Principal

Leeftijdsdistributie van bedrijfsleiders

Ratio vrouwen/mannen

Man	22
Vrouw	10

Waarvan leden van het uitvoerend comité

Man	5
Vrouw	4

Waarvan bestuurders

Man	8
Vrouw	1

ESG Refinitiv

B-

Milieu

Emissies

Innovatie

Gebruik van middelen

Bedrijfsvoering

MVO-strategie

Beheer

Aandeelhouders

Controverse

Gilead Sciences, Inc. is gespecialiseerd in de ontwikkeling, productie en marketing van therapeutische producten. De netto-omzet kan als volgt worden uitgesplitst naar inkomstenbron - verkoop van geneesmiddelen (98,9%): voor de behandeling van HIV (63% van de netto-omzet), COVID-19 (20,4%), hepatitis C-virus (6,6%), hepatitis B-virus (3,6%) en overige (6,4%; voornamelijk cytomegalovirus retinitis, en gevorderd Kaposi sarcoom als gevolg van HIV); - overige (1,1%): met name royalty's en inkomsten uit onderzoeks- en ontwikkelingsdiensten en uit uitbestede productie van therapeutische producten. De netto-omzet is als volgt geografisch verdeeld: de Verenigde Staten (69,2%), Europa (16,4%) en overige (14,4%).

Werknemers

18.000

Sector

Farmaceutische producten

Agenda

13-09-2024 - Détachement de dividend

Gerelateerde indices

S&P 500

Meer informatie over het bedrijf